Hodgkin lymphoma (HL) is a B-cell lymphoid malignancy. Although treatment outcomes for HL are generally favorable, relapsed/refractory cases can be challenging to manage. Immunotherapy has emerged as an important treatment option, especially for patients who do not respond to traditional therapies. In this chapter, we focus on immune checkpoint inhibitors. Nivolumab and Pembrolizumab are monoclonal antibodies that target PD-1, while Ipilimumab targets CTLA-4. By inhibiting the PD-1/PD-L1 pathway, these therapies enable the immune system to recognize and attack cancer cells. The use of immune checkpoint inhibitors has improved outcomes in relapsed/refractory cases. The most common side effects include diarrhea and infusion reactions. Overall, immunotherapy has revolutionized the treatment of HL.